Warberg Asset Management’s Windtree Therapeutics WINT Stock Holding History
Bought
Maintained
Sold
Other funds holding WINT
TRCT
FDCDDQ
IA
GI
PA
Warberg Asset Management's WINT Position: Q1 2023 in Review
Warberg Asset Management sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 1 share — an estimated $4.26K sold.
Warberg Asset Management first reported a position in WINT in Q4 2022 and held it in 1 quarter. The position peaked at $4.26K in Q4 2022. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.
- Warberg Asset Management reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
- Warberg Asset Management sold 1 Windtree Therapeutics share in Q1 2023, an estimated $4.26K.
- Warberg Asset Management first reported a position in Windtree Therapeutics in Q4 2022 and held it in 1 quarter.
- Warberg Asset Management's Windtree Therapeutics position peaked at $4.26K in Q4 2022.
- 2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.
Based on Warberg Asset Management's 13F filing for Q1 2023, filed 15 May 2023.